Hims & Hers warns it may stop selling compounded weight-loss drugs
Hims & Hers said on Monday that it may no longer be able to sell compounded versions of the weight-loss drug made by Novo Nordisk because its pathway to do so closed when the U.S. FDA declared Friday that the drug's shortage was over.
One popular option, Weight Loss by Hers, is a holistic program personalized for you. The program features four pillars of ...
Weight loss is a common New Year's resolution and studies ... But as GLP-1 drugs spike in popularity, the FDA says hazardous counterfeits are also on the rise and pose serious health risks.
Eli Lilly has lowered the price of its weight-loss drug Zepbound for patients paying out of pocket and introduced two new ...
Eli Lilly is expanding the supply and cutting the costs of its weight-loss drug Zepbound, broadening access to more patients ...
After the FDA removed semaglutide injection products from a shortage list, compounders like Hims have 60-90 days to stop ...
Technology is transforming every aspect of our lives, and weight loss is no exception. From AI-driven meal plans to wearable fitness trackers, the future of weight loss is becoming more personalized, ...
This is similar to what the FDA has granted compounding pharmacies making copies of Eli Lilly's diabetes and weight loss drug tirzepatide, amid an ongoing lawsuit brought by outsourcing ...
Shares of Hims & Hers Health tumbled 18% premarket on Tuesday as Wall Street analysts questioned the telehealth provider's ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback